Skip to Content

Rexulti Approval History

  • FDA approved: Yes (First approved July 10th, 2015)
  • Brand name: Rexulti
  • Generic name: brexpiprazole
  • Dosage form: Tablets
  • Company: Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S
  • Treatment for: Schizophrenia, Depression, Major Depressive Disorder

Rexulti (brexpiprazole) is a serotonin-dopamine activity modulator (SDAM) for the treatment of schizophrenia and the adjunctive treatment of major depressive disorder.

Schizophrenia is a chronic mental illness that can cause delusions and hallucinations. Major Depressive Disorder is a serious psychiatric condition that can lead to persistent feelings of sadness, frustration or anger. Rexulti is approved for use as monotherapy for the treatment of schizophrenia, and as adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).

Rexulti is an atypical antipsychotic that works through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. It is considered a second generation version of aripiprazole (Abilify), and with slightly different activity at the serotonin and dopamine receptors, could mean an improved clinical profile with fewer side effects such as restlessness.

The safety and efficacy of Rexulti was studied in four completed placebo-controlled clinical phase III studies – two studies as adjunctive therapy to antidepressants in MDD and two studies in schizophrenia. Rexulti was demonstrated to be superior to placebo for both conditions at specific dosages.

Rexulti tablets are taken once daily with or without food. A lower dose is given to start, and then gradually increased over time to the target dosage.

Common side effects include weight gain and akathisia, an inner sense of restlessness.

Development History and FDA Approval Process for Rexulti

Sep 23, 2016Approval U.S. FDA Approves Labeling Update of Rexulti (brexpiprazole) for Maintenance Treatment of Schizophrenia
Jul 10, 2015Approval FDA Approves Rexulti (brexpiprazole) for Schizophrenia and Adjunctive Treatment for Major Depressive Disorder
Apr 17, 2015Results of Phase III Study of Brexpiprazole in Adult Patients With Schizophrenia Published in American Journal of Psychiatry
Sep 24, 2014FDA Accepts Filing for Review of Brexpiprazole
Jul 14, 2014Otsuka and Lundbeck Submit NDA for Brexpiprazole

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.